Dr Lalchandani Labs
- Market cap
- ₹ 6 Cr.
- P/E
- 101.8x
- P/B
- 0.44x
- 52-week range
- 5.81 – 17.99
- ROE
- 1%
- ROCE
- 0.8%
- Dividend yield
- 0%
- Debt / equity
- 0.15
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE SME
About
Dr Lalchandani Labs Limited is an India-based company, which is a provider of diagnostic and related healthcare tests and services in Delhi/NCR. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, virology, cytology, other pathological investigations and immunoassay, immuno-histochemistry, molecular pathology, DNA and genetic testing. Through its integrated network, it offers patients and healthcare providers a range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The Company has its own blood banking services through its sister concern CPC blood bank. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Dr Lalchandani Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)101.8 against a typical 21: pricier than most peers (1st = cheapest).32nd of 34
- Sales growth+2.4% against a typical +19.1% from a year earlier.25th of 31
- Profit growth−118.3% against a typical +25.2% from a year earlier.24th of 24
- Share price, 3 months−4.6% against a typical −7.7%.12th of 33
- Size₹ 6 Cr. market value against a typical ₹ 83 Cr. (1st = largest).32nd of 34
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 7 | 8 | 3 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 2 |
| Expenses | 2 | 5 | 6 | 3 | 2 | 3 | 2 | 1 | 2 | 2 | 2 | 2 |
| Operating Profit | 1 | 2 | 2 | 0 | −0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| OPM % | 21% | 23.6% | 24.3% | 13.8% | −7.9% | 9.4% | 12.8% | 50% | 25.4% | 21.9% | 12.7% | 6.1% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 1 | 1 | −0 | −1 | −1 | −0 | 1 | 0 | 0 | 0 | −0 |
| Tax % | 24.1% | 27.8% | 25.2% | −22.2% | 0% | 0% | 0% | 0% | 23.8% | −35% | 26.9% | −17.7% |
| Net Profit | 0 | 1 | 1 | −0 | −1 | −1 | −0 | 1 | 0 | 0 | 0 | −0 |
| EPS in Rs | 0.26 | 0.91 | 1.23 | −0.15 | −1.11 | −0.68 | −0.1 | 0.82 | 0.17 | 0.31 | 0.23 | −0.15 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- −16%
- 3 Years
- −6%
- TTM
- −6%
- 10 Years
- —
- 5 Years
- −43%
- 3 Years
- 27%
- TTM
- −80%
- 10 Years
- —
- 5 Years
- −18%
- 3 Years
- −31%
- TTM
- —
- 10 Years
- —
- 5 Years
- −2%
- 3 Years
- −1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Dr Lalchandani Labs | ₹ 7.07 | ₹ 6 Cr. | 101.8x | 0.4x | 1% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 59.9x | 12.4x | — | 8.1% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 61x | 8.4x | — | 16.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 86.8x | 7.9x | — | 7.4% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 55x | 5.9x | — | 11.3% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 66x | 9.3x | — | 11.8% |
Management
- Arjan Lalchandani
- Executive Chairman of the Board, Managing Director
- Mohit Lalchandani
- Chief Executive Officer, Whole Time Director
- Anchal Gupta
- Chief Financial Officer, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.